Thermo Fisher Scientific Cytokeratin 5/6 Antibody Cocktail

Applications

Tested Dilution

Publications

Immunohistochemistry (Paraffin) (IHC (P))

Ready-to-use 150-200 µL

-

Product Specifications

Host/Isotype

Mouse / IgG1, kappa/IgG2a, kappa

Class

Cocktail

Type

Antibody

Clone

ZM43

Immunogen

Recombinant human Cytokeratin 5 (KRT5) protein fragment (around aa 318-491); Recombinant full-length human Cytokeratin 6A (KRT6A) protein

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Storage conditions

2-8°C

Shipping conditions

Wet ice

Product Specific Information

This product is diluted and in a ready-to-use formulation.

A recommended positive control tissue for this product is Epithelial cell (Tonsil, Prostate, Pancreas, colon, Thyroid, etc.), however positive controls are not limited to this tissue type.

The primary antibody is intended for laboratory professional use in the detection of the corresponding protein in formalin-fixed, paraffin-embedded tissue stained in manual qualitative immunohistochemistry (IHC) testing. This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using non-immunological histochemical stains.

It recognizes polypeptides of 58 kDa and 56 kDa, identified as cytokeratin 5 and 6 respectively. It shows no reaction with keratin 1, 8, or 19. It stains the basal cells of squamous and glandular epithelia, part of stratum spinosum of squamous epithelium, myoepithelium, and mesothelium. It does not stain adenous epithelium. Therefore, this antibody can be used to distinguish squamous carcinoma from adenocarcinoma, and to differentiate epithelioid mesothelioma from non-epithelioid mesothelioma and adenocarcinoma. It is also a useful antibody to distinguish benign ductal hyperplasias from non-invasive neoplastic proliferations. Positive tissue: Skin

Antibody is used with formalin-fixed and paraffin-embedded sections. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended. In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody (link antibody), an enzyme complex and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.

A positive tissue control must be run with every staining procedure performed. This tissue may contain both positive and negative staining cells or tissue components and serve as both the positive and negative control tissue. External Positive control materials should be fresh autopsy/biopsy/surgical specimens fixed, processed and embedded as soon as possible in the same manner as the patient sample (s). Positive tissue controls are indicative of correctly prepared tissues and proper staining methods. The tissues used for the external positive control materials should be selected from the patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed to ensure detection of subtle changes in the primary antibody sensitivity from instability or problems with the staining methodology. A tissue with weak positive staining is more suitable for optimal quality control and for detecting minor levels of reagent degradation.

Internal or external negative control tissue may be used depending on the guidelines and policies that govern the organization to which the end user belongs to. The variety of cell types present in many tissue sections offers internal negative control sites, but this should be verified by the user. The components that do not stain should demonstrate the absence of specific staining, and provide an indication of non-specific background staining. If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.

Target Information

The protein encoded by this gene is a member of the keratin gene family. The type II cytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed during differentiation of simple and stratified epithelial tissues. This type II cytokeratin is specifically expressed in the basal layer of the epidermis with family member KRT14. Mutations in these genes have been associated with a complex of diseases termed epidermolysis bullosa simplex. The type II cytokeratins are clustered in a region of chromosome 12q12-q13.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.